Uloric is a pill-based prescription medication for gout. Gout is a type of arthritis that is caused by high uric acid levels in the blood. When uric acid accumulates in a patient’s tendons and joints, it creates stiffness, swelling, and pain. By lowering the uric acid levels, Uloric keeps these buildups from happening, making it an effective long-term treatment for gout.
However, Uloric comes with severe side effects and complications, including:
- Gout flares,
- Liver problems,
- An increased risk for major cardiovascular events, including heart attacks, strokes, and unstable anginas, and
- Severe allergic reactions, including Stevens-Johnson Syndrome.
Years after its approval in the U.S., clinical trials showed that Uloric came with an increased risk for fatal heart problems– a risk that was not prominently disclosed by Takeda in the warning label for Uloric. Since the danger has become apparent, the U.S. Food and Drug Administration (FDA) added a box warning on Uloric’s label and issued a safety announcement about the dangers.
Since then, numerous claims have been filed against Takeda for their failure to warn people of the risks of taking Uloric. Drug companies like Takeda Pharmaceutical have a legal duty to disclose the risks of taking their products. Patients and doctors rely on these disclosures to make appropriate prescriptions and informed health decisions.
But pharmaceutical companies also know that disclosing all of the risks associated with the drugs they sell are likely to deter patients and consumers and hurt the company’s bottom line by reducing sales. So they often look for whatever way they can to avoid including a warning on the drug’s labeling.
Claimant Had taken Uloric after 2010
Claimant had a heart attack
Claimant had strokes
Claimant has not signed up with another Attorney